Funding for this research was provided by:
Research to Prevent Blindness (Unrestricted grant)
Received: 11 November 2020
Accepted: 23 March 2021
First Online: 1 April 2021
: The study protocol was approved by the Institutional Review Board of the University of California Irvine.
: No consent for publication was obtained from the patients as all the images used are entirely unidentifiable and there are no personal data included in the manuscript that can be traced to an individual patient.
: *Baruch D. Kuppermann is consultant to Alcon, Alimera, Allegro, Allergan, Genentech, Glaukos, GSK, Neurotech, Novagali, Novartis, Ophthotech, Pfizer, Regeneron, Santen, SecondSight, Teva, ThromboGenics. *The rest of the authors declare that they have no competing interests.